Court Denies Bail to Doctor in MP Cough Syrup Deaths, Cites Prima Facie Case and Kickback Allegations

CHHINDWARA, MADHYA PRADESH – A sessions court in Madhya Pradesh has rejected the bail application of a senior government paediatrician, Dr. Praveen Soni, arrested in connection with the deaths of more than 20 children allegedly caused by a contaminated cough syrup. The Parasia Sessions Court, presided over by Additional Sessions Judge Goutam Kumar Gujre, found that a prima facie case was established against the doctor and deemed the ongoing investigation and the gravity of the charges sufficient grounds to deny pre-trial release.

The case, which has sent shockwaves through the medical and legal communities, centres on the prescription of 'Coldrif' cough syrup, which was later found to contain a toxic industrial solvent, Diethylene Glycol (DEG), at a dangerously high concentration of 48.6%. The court’s order on October 8, 2025, highlights a confluence of alleged medical negligence, regulatory violations, and financial impropriety that culminated in a public health tragedy.

The Core Allegations and Prima Facie Findings

Dr. Soni, a paediatrician with over three decades of experience at the Government Community Health Centre in Parasia, was arrested following an FIR filed on October 4, 2025. He faces charges under the Bharatiya Nyaya Sanhita, 2023 (BNS), including Section 105 (culpable homicide not amounting to murder) and Section 276 (knowingly selling a drug as a different preparation), alongside Section 27-A of the Drugs and Cosmetics Act, 1940.

The prosecution’s case, presented to the court, rested on several key pillars that Judge Gujre found compelling for the purpose of the bail hearing.

First, the court noted the direct violation of a critical central government directive. On December 18, 2023, the Directorate General of Health Services (DGHS) had issued clear guidelines to all states, explicitly prohibiting the prescription of Fixed Dose Combination (FDC) medicines, like Coldrif, to children under the age of four. The police alleged, and the court acknowledged, that Dr. Soni continued to prescribe the syrup to young children despite this national advisory.

Second, and perhaps most damningly, the prosecution argued that Dr. Soni persisted in prescribing the syrup even after observing its devastating side effects. The court record reflects a tragic pattern: children treated by the doctor for common ailments developed acute kidney disorders, difficulty urinating, and elevated creatinine levels. Many were subsequently referred to a hospital in Nagpur, where they succumbed to acute kidney failure. The police submitted that the first child death was reported on August 29, 2025, but the prescriptions allegedly continued through September and early October.

In its order, the court observed: "Even after receiving knowledge of the deaths, the prescription of the same formulation continued. The investigation was found incomplete, and the alleged offence is grave in nature."

Allegations of Financial Kickbacks and Conflicts of Interest

The case takes on a more sinister dimension with the police’s allegation of a financial motive. According to the prosecution, Dr. Soni admitted during interrogation to receiving a 10% commission from the Tamil Nadu-based manufacturer, Sresan Pharmaceutical Manufacturer, for prescribing Coldrif syrup.

This claim is further bolstered by evidence of potential conflicts of interest. The court took note of police findings that a medical shop located adjacent to Dr. Soni's private clinic is owned by his relatives, and that the district's stockist for the contaminated syrup was also a family member. These connections, the prosecution argued, suggest a deliberate and financially motivated promotion of a specific, and ultimately lethal, drug.

The court stated that as per Dr. Soni's memorandum, he received the commission, and this fact, combined with the familial links to the supply chain, warranted further investigation, making bail inappropriate at this stage.

The Defense: A Doctor's Duty vs. Systemic Failure

In his bail application, Dr. Soni, represented by Advocate Pawan Kumar Shukla, positioned himself as a victim of a larger systemic failure. The defense argued that Dr. Soni, a government doctor with a long and unblemished career, had prescribed a medication that was duly approved and had been in use for over 15 years. His counsel contended that the doctor had prescribed the syrup in good faith, completely unaware of the contamination in a specific batch.

"The contaminated batch of the drug was manufactured by the company, of which he had no knowledge," his lawyer argued in court. "Drug quality testing is the responsibility of the Drug Controller Department."

This argument has found resonance within parts of the medical community. The Indian Medical Association (IMA) has questioned whether Dr. Soni is being made a scapegoat, arguing that the ultimate responsibility for ensuring drug safety lies with the manufacturer and regulatory bodies, not the prescribing physician. They assert that placing the entire burden of a contaminated drug crisis on a single doctor is unjust when it points to a catastrophic regulatory lapse.

The Court’s Reasoning for Bail Denial

In rejecting the bail plea, Judge Gujre balanced the presumption of innocence against the overwhelming public interest and the integrity of the ongoing investigation. The court’s decision was rooted in several well-established legal principles for denying bail:

• Existence of a Prima Facie Case: The court found substantial material on record—including the DGHS directive, the pattern of patient harm, and the commission allegations—to conclude that a prima facie case was clearly made out.
• Gravity of the Offense: The death of over 20 children elevates the crime to one of extreme severity, a factor that weighs heavily against granting pre-trial liberty.
• Risk of Tampering with Evidence: Citing the doctor's local influence, medical connections, and the alleged involvement of his relatives in the supply chain, the court noted a tangible risk that he could obstruct justice or influence witnesses if released.
• Incomplete Investigation: The Special Investigation Team (SIT) is still probing the roles of the manufacturer, distributors, and other medical professionals. Granting bail at this crucial juncture, the court reasoned, could impede the investigation's progress.

The court concluded, "Considering the facts, circumstances, and the gravity of the offence, it is not appropriate to grant bail at this stage."

Broader Legal and Regulatory Implications

The Chhindwara cough syrup tragedy and the subsequent legal proceedings against Dr. Soni raise profound questions about liability in India's pharmaceutical supply chain. While the manufacturer, Sresan Pharmaceutical, has had its license revoked and its owner is under investigation, the prosecution of a prescribing doctor for what is primarily a manufacturing defect is a significant legal development.

This case will likely become a critical reference point in medico-legal jurisprudence, forcing a re-evaluation of the extent of a doctor's duty. Does a physician's responsibility end with prescribing an approved drug, or does it extend to heeding broader health advisories and recognizing adverse event patterns, especially when financial incentives are involved?

For legal practitioners, this case underscores the increasing criminalization of medical practice and the complex interplay between professional negligence, regulatory compliance, and criminal intent. The outcome of Dr. Soni's trial will have far-reaching implications for how courts assign culpability when systemic failures in drug manufacturing and regulation lead to public health disasters.